CN1688582A - 稠合吡咯－嘧啶衍生物 - Google Patents

稠合吡咯－嘧啶衍生物 Download PDF

Info

Publication number
CN1688582A
CN1688582A CN 03823367 CN03823367A CN1688582A CN 1688582 A CN1688582 A CN 1688582A CN 03823367 CN03823367 CN 03823367 CN 03823367 A CN03823367 A CN 03823367A CN 1688582 A CN1688582 A CN 1688582A
Authority
CN
China
Prior art keywords
c1
alkyl
amino
optionally substituted
group
Prior art date
Application number
CN 03823367
Other languages
English (en)
Chinese (zh)
Other versions
CN100384846C (zh
Inventor
M·施马达
T·穆拉塔
K·富基卡米
H·楚吉施塔
N·奥莫里
I·卡托
M·缪拉
K·乌尔巴恩斯
F·甘特纳
K·巴康
Original Assignee
拜尔药品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP02021861.6 priority Critical
Priority to EP02021861 priority
Application filed by 拜尔药品公司 filed Critical 拜尔药品公司
Publication of CN1688582A publication Critical patent/CN1688582A/zh
Application granted granted Critical
Publication of CN100384846C publication Critical patent/CN100384846C/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
CN 03823367 2002-09-30 2003-09-18 稠合吡咯-嘧啶衍生物 CN100384846C (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02021861.6 2002-09-30
EP02021861 2002-09-30

Publications (2)

Publication Number Publication Date
CN1688582A true CN1688582A (zh) 2005-10-26
CN100384846C CN100384846C (zh) 2008-04-30

Family

ID=32039115

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 03823367 CN100384846C (zh) 2002-09-30 2003-09-18 稠合吡咯-嘧啶衍生物

Country Status (33)

Country Link
US (2) US7511041B2 (und)
EP (2) EP1549652B1 (und)
JP (1) JP4790266B2 (und)
KR (1) KR101059652B1 (und)
CN (1) CN100384846C (und)
AR (2) AR041426A1 (und)
AT (2) AT511510T (und)
AU (1) AU2003293310B2 (und)
BR (2) BR0314830A (und)
CA (1) CA2499134C (und)
CY (2) CY1109790T1 (und)
DE (1) DE60324296D1 (und)
DK (2) DK2042504T3 (und)
EC (2) ECSP055768A (und)
ES (2) ES2367141T3 (und)
HK (1) HK1084393A1 (und)
HR (2) HRP20050375B1 (und)
IL (1) IL166855A (und)
MA (1) MA27483A1 (und)
MX (1) MXPA05001808A (und)
MY (1) MY140756A (und)
NO (1) NO331457B1 (und)
NZ (1) NZ539062A (und)
PE (1) PE00892005A1 (und)
PL (1) PL226562B1 (und)
PT (2) PT2042504E (und)
RU (1) RU2326881C9 (und)
SI (2) SI2042504T1 (und)
TW (1) TWI327570B (und)
UA (1) UA82205C2 (und)
UY (1) UY28001A1 (und)
WO (1) WO2004029055A1 (und)
ZA (1) ZA200503306B (und)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101990577A (zh) * 2007-09-19 2011-03-23 波士顿大学理事会;犹他州立大学研究基金会 鉴定肺病药物开发的新途径
CN102459253A (zh) * 2009-04-30 2012-05-16 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
CN103339133A (zh) * 2010-11-11 2013-10-02 拜耳知识产权有限责任公司 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
CN103370320A (zh) * 2010-11-11 2013-10-23 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
CN103649091A (zh) * 2011-04-05 2014-03-19 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐
CN105130998A (zh) * 2015-09-25 2015-12-09 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997A (zh) * 2015-09-25 2015-12-09 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN107074776A (zh) * 2014-11-07 2017-08-18 拜耳制药股份公司 Copanlisib及其二盐酸盐的合成
US9920374B2 (en) 2005-04-14 2018-03-20 Trustees Of Boston University Diagnostic for lung disorders using class prediction

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CA2537124C (en) * 2003-08-29 2012-08-07 Mitsui Chemicals, Inc. Agricultural/horticultural insecticide and method for using the same
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
AU2005293607A1 (en) 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh PI3 kinases
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
CL2007001167A1 (es) * 2006-04-26 2008-01-25 Genentech Inc Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica.
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
JP2010539239A (ja) * 2007-09-17 2010-12-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体
EP2244721A4 (en) * 2008-01-14 2017-01-18 Bayer Intellectual Property GmbH Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
WO2009128520A1 (ja) * 2008-04-18 2009-10-22 塩野義製薬株式会社 Ｐ１３ｋ阻害活性を有する複素環化合物
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
CA2735932C (en) * 2008-09-30 2013-07-09 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
BRPI0915273A2 (pt) * 2008-11-11 2015-08-04 Je Il Pharmaceutical Co Ltd Derivado tricíclico inovador ou seus sais farmaceuticamente aceitáveis, seu método de preparação e composição farmacêutica que os contém.
CN104042618B (zh) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 恶性血液病的治疗
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102395585A (zh) * 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
JP2012521994A (ja) 2009-03-24 2012-09-20 ギリアード カリストガ エルエルシー ２−プリニル−３−トリル−キナゾリノン誘導体のアトロプ異性体および使用方法
US8546409B2 (en) 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
EP2456443A1 (en) 2009-07-21 2012-05-30 Gilead Calistoga LLC Treatment of liver disorders with pi3k inhibitors
KR20120063515A (ko) * 2009-09-09 2012-06-15 아빌라 테라퓨틱스, 인크. Ｐｉ３ 키나제 억제제 및 이들의 용도
JP5886271B2 (ja) * 2010-04-16 2016-03-16 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン含有組合せ品
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
NZ610018A (en) * 2010-11-11 2016-03-31 Bayer Ip Gmbh Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
UY33984A (es) 2011-04-05 2012-10-31 Bayer Pharma AG Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
ES2708350T3 (es) 2013-04-08 2019-04-09 Bayer Pharma AG Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas para el tratamiento de linfomas
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
EA201690990A1 (ru) 2013-12-20 2016-11-30 Джилид Калистога Ллс Способы получения ингибиторов фосфатидилинозитол-3-киназы
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142312A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
US20190092775A1 (en) 2016-03-08 2019-03-28 Bayer Pharma Aktiengesellschaft 2-amino-n- [7-methoxy-2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
EP3515911A1 (en) 2016-09-23 2019-07-31 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2018153980A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft Formulations of copanlisib
WO2019073031A1 (en) 2017-10-13 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
CN1033644C (zh) 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
EP0771204A4 (en) 1994-08-12 1999-10-20 Pro Neuron Inc Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides
AU709190B2 (en) * 1996-01-29 1999-08-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
US5932584A (en) 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
ES2527754T3 (es) 2000-04-25 2015-01-29 Icos Corporation Inhibidores de la isoforma delta de la fosfatidilinositol 3-quinasa humana
CN100345830C (zh) * 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9920374B2 (en) 2005-04-14 2018-03-20 Trustees Of Boston University Diagnostic for lung disorders using class prediction
CN101990577A (zh) * 2007-09-19 2011-03-23 波士顿大学理事会;犹他州立大学研究基金会 鉴定肺病药物开发的新途径
CN102459253B (zh) * 2009-04-30 2015-03-25 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
CN102459253A (zh) * 2009-04-30 2012-05-16 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
CN103339133A (zh) * 2010-11-11 2013-10-02 拜耳知识产权有限责任公司 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
CN103370320A (zh) * 2010-11-11 2013-10-23 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
CN103339133B (zh) * 2010-11-11 2016-06-15 拜耳知识产权有限责任公司 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
CN103649091A (zh) * 2011-04-05 2014-03-19 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐
CN103649091B (zh) * 2011-04-05 2016-06-22 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐
CN107074776A (zh) * 2014-11-07 2017-08-18 拜耳制药股份公司 Copanlisib及其二盐酸盐的合成
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法
CN105130998A (zh) * 2015-09-25 2015-12-09 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997A (zh) * 2015-09-25 2015-12-09 苏州明锐医药科技有限公司 一种库潘尼西的制备方法

Also Published As

Publication number Publication date
AU2003293310B2 (en) 2010-04-01
NO331457B1 (no) 2012-01-09
RU2005113165A (ru) 2005-10-10
US20060128732A1 (en) 2006-06-15
DK1549652T3 (da) 2009-02-23
EP1549652B1 (en) 2008-10-22
ECSP055768A (es) 2005-08-11
BRPI0314830B1 (pt) 2018-03-27
MA27483A1 (fr) 2005-08-01
ECSP11005768A (es) 2011-03-31
AT511510T (de) 2011-06-15
IL166855A (en) 2014-05-28
CN100384846C (zh) 2008-04-30
RU2326881C9 (ru) 2009-04-10
WO2004029055A1 (en) 2004-04-08
PT2042504E (pt) 2011-09-07
CA2499134C (en) 2011-12-20
US20090270388A1 (en) 2009-10-29
AR041426A1 (es) 2005-05-18
KR101059652B1 (ko) 2011-08-25
HRP20050375A2 (en) 2006-05-31
TWI327570B (en) 2010-07-21
DE60324296D1 (de) 2008-12-04
RU2326881C2 (ru) 2008-06-20
UY28001A1 (es) 2004-04-30
EP2042504B1 (en) 2011-06-01
CY1109790T1 (xx) 2014-09-10
PL375935A1 (xx) 2005-12-12
US8129386B2 (en) 2012-03-06
CA2499134A1 (en) 2004-04-08
AT411996T (de) 2008-11-15
TW200413379A (en) 2004-08-01
BR0314830A (pt) 2005-08-16
HK1084393A1 (en) 2009-03-27
JP4790266B2 (ja) 2011-10-12
SI1549652T1 (sl) 2009-04-30
EP2042504A1 (en) 2009-04-01
HRP20050375B1 (hr) 2014-03-14
MY140756A (en) 2010-01-15
PE00892005A1 (es) 2005-04-20
DK2042504T3 (da) 2011-09-19
MXPA05001808A (es) 2005-08-16
EP1549652A1 (en) 2005-07-06
ES2312843T3 (es) 2009-03-01
JP2006508063A (ja) 2006-03-09
ZA200503306B (en) 2006-07-26
PT1549652E (pt) 2008-12-15
CY1112174T1 (xx) 2015-12-09
AU2003293310A1 (en) 2004-04-19
HRP20131159B1 (hr) 2019-11-01
UA82205C2 (en) 2008-03-25
AR072458A2 (es) 2010-09-01
KR20050067404A (ko) 2005-07-01
ES2367141T3 (es) 2011-10-28
NO20052076L (no) 2005-04-27
US7511041B2 (en) 2009-03-31
SI2042504T1 (sl) 2011-10-28
NZ539062A (en) 2007-05-31
HRP20131159A2 (hr) 2014-05-23
PL226562B1 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
ES2563458T3 (es) Compuestos heterocíclicos y sus usos
KR101903305B1 (ko) 피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
ES2446417T3 (es) Derivados de quinolina o quinoxalina sustituidos en 3 y su uso como inhibidores de fosfatidilinositol 3-cinasa (PI3K)
KR100908155B1 (ko) 히스타민 ｈ3 수용체 리간드로서 유용한테트라하이드로나프티리딘 유도체
KR101566840B1 (ko) 페닐 아미노 피리미딘 화합물 및 이의 용도
JP5060294B2 (ja) Ｐｌｋインヒビターとしてのピリミジン化合物
EP2178865B1 (en) 5-membered heterocyclic amides and related compounds
KR100850812B1 (ko) 신규 화합물
JP5572388B2 (ja) キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
JP3987829B2 (ja) グルコキナーゼ化合物
ES2396135T3 (es) Compuestos y composiciones como inhibidores de proteínas cinasas
CA2546987C (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity
US20080171743A1 (en) Transcutaneous immunostimulation
US7592352B2 (en) Substituted thieno and furo-pyridines
KR101530117B1 (ko) 야누스 키나제 억제제 화합물 및 방법
US20080039450A1 (en) Compounds
US20110034689A1 (en) N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases
AU2008302099B2 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
US20100227858A1 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ES2445199T3 (es) Derivados de benzpirazol como inhibidores de PI3-quinasas
DK2376478T3 (en) Pyridyloxyindoline inhibitors for VEGF-R2 and its use in the treatment of diseases
US8536168B2 (en) Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
TWI434846B (zh) 新穎化合物
AU2008273891B2 (en) Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
ES2527754T3 (es) Inhibidores de la isoforma delta de la fosfatidilinositol 3-quinasa humana

Legal Events

Date Code Title Description
C06 Publication
C10 Request of examination as to substance
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084393

Country of ref document: HK

C14 Granted
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1084393

Country of ref document: HK

ASS Succession or assignment of patent right

Free format text: FORMER OWNER: BAYER PHARMACEUTICAL CO., LTD.

Effective date: 20100420

Owner name: BAYER SCHERING PHARMACEUTICAL CO., LTD.

C41 Transfer of the right of patent application or the patent right
COR Bibliographic change or correction in the description

Free format text: CORRECT: ADDRESS; FROM: CONNECTICUT STATE, U.S.A TO: BERLIN, GERMANY

C56 Change in the name or address of the patentee

Owner name: BAYER PHARMACEUTICALS AG

Free format text: FORMER NAME: BAYER SCHERING PHARMA AG

C41 Transfer of the right of patent application or the patent right
ASS Succession or assignment of patent right

Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Effective date: 20130322